Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground

Executive Summary

A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content
Advertisement

Related Content

Off-Label Reprint Guidance: “Definitely Improved,” But Will Waxman Fight On?
Off-Label Reprint Guidance: “Definitely Improved,” But Will Waxman Fight On?
FDA’s Off-Label Dissemination Guidance Opens “Loophole” – Rep. Waxman
Off-Label Promotion Cases Need Better Oversight In Justice Dept., WLF Says
Schering-Plough Faces Criminal Case; Off-Label Promotion May Be One Count
WLF Appeals Court Decision Leaves Free Speech Question Open
WLF Appeals Court Decision Leaves Free Speech Question Open
Advertisement
UsernamePublicRestriction

Register

PS049337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel